From AI-powered diagnostics to next-generation surgical robotics and novel drug delivery systems, UK medtech companies are tackling some of the most pressing medical challenges of our time.

In 2023, the Department of Health and Social Care launched its first-ever Medical Technology Strategy, underlining the government’s commitment to supporting medtech innovation and scaling adoption across the NHS. Since then, funding has continued to flow into the sector, and private companies are playing a central role in shaping the future of healthcare.

What is medtech?

Medtech — short for medical technology — refers to any technology designed to support the prevention, diagnosis, monitoring, or treatment of health conditions. It covers a wide spectrum of tools and devices, from wearable monitors and imaging equipment to surgical robots and AI-driven drug design platforms.

In recent years, the term has become increasingly associated with high-tech, next-generation innovations that aim to improve clinical outcomes and enhance the patient experience. Today’s medtech solutions are helping to detect disease earlier, enable more personalised treatment, and streamline care delivery at scale.

The UK has long been a global leader in medical innovation. From the invention of the MRI scanner to advances in sequencing and diagnostics, the country’s universities, research centres, and startups have played a pivotal role in shaping the industry. Ongoing government support, strategic investment, and cross-sector collaboration continue to fuel the UK’s dynamic medtech ecosystem.

The UK’s top medtech companies

10. F2G

Year founded: 1998
Location: Macclesfield
Funds raised: £283m

F2G is a biopharmaceutical company developing novel antifungal therapies to treat life-threatening invasive fungal infections. Spun out from the University of Manchester, it is focused on addressing a global unmet medical need with first-in-class agents that differ from existing treatments in their mechanism of action.

In September 2024, F2G secured $100m in funding to advance the commercialisation of Olorofim in the US. The company has raised £283m through 11 equity fundraisings.

09. Quanta

Year founded: 2015
Location: Warwick
Funds raised: £294m

Quanta Dialysis Technologies has developed a portable haemodialysis device designed to give patients greater access to treatment, whether in clinical environments or at home. The company has raised £294m across six funding rounds.

08. Exscientia

Year founded: 2012
Location: Dundee
Funds raised: £300m

Exscientia is a pioneer in AI-driven drug discovery, using advanced machine learning to design and prioritise small molecule drug candidates. The company was the first in the world to bring an AI-designed molecule into clinical trials and continues to lead the emerging field of pharmatech, where AI meets drug development.

To date, Exscientia has raised £300m across seven equity fundraisings.

07. Verdiva Bio

Year founded: 2024
Location: Guildford
Funds raised: £335m

Verdiva Bio is a next-generation biotech company developing cardiometabolic therapies, with a focus on obesity treatment. Launched in 2024, the company quickly attracted global attention with a £335m Series A round — one of the largest early-stage fundraises in UK medtech history.

06. Immunocore

Year founded: 2015
Location: Abingdon
Funds raised: £410m

Immunocore is a clinical-stage biotech developing T cell receptor-based medicines to treat cancer, infectious diseases, and autoimmune conditions. The company’s lead therapy, tebentafusp, has gained international attention as a potential breakthrough in oncology.

Immunocore has raised £410m across 12 funding rounds.

05. Isomorphic Labs

Year founded: 2021
Location: London
Funds raised: £464m

A spinout from Google’s DeepMind, Isomorphic Labs is building a drug design platform that uses AI to model and engineer novel pharmaceuticals. With its cutting-edge computational biology approach, the company is working to radically speed up and improve the drug discovery process.

Isomorphic Labs raised £464m in a single fundraising round in March 2025.

04. Autolus Therapeutics

Year founded: 2015
Location: London
Funds raised: £639m

Autolus Therapeutics develops T-cell therapies for cancer, using advanced cell programming to target haematological malignancies and solid tumours. Spun out of University College London, the company has become a leader in the CAR-T therapy space.

It has raised £639m through five funding rounds.

03. Bicycle Therapeutics

Year founded: 2015
Location: Cambridge
Funds raised: £673m

Bicycle Therapeutics is pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) platform. These ultra-small molecules offer the targeting power of antibodies with the precision and scalability of small molecules — opening up new avenues in oncology and radiopharmaceuticals.

The company has raised £673m through seven equity rounds.

02. Oxford Nanopore Technologies

Year founded: 2015
Location: Oxford
Funds raised: £1.01b

Oxford Nanopore Technologies is transforming genomics with its portable DNA and RNA sequencing devices. From academic labs to global public health efforts, its real-time sequencing technology is used across the world to analyse biological samples with speed and flexibility.

The company has raised over £1bn across 19 fundraisings.

01. CMR Surgical

Year founded: 2014
Location: Cambridge
Funds raised: £1.03b

Topping the list is CMR Surgical, a global leader in robotic-assisted surgery best known for its flagship Versius system. Designed to support minimally invasive procedures, Versius has received regulatory approval in the US, UK, and across Europe — and is rapidly gaining adoption in hospitals worldwide.

The company has raised £1.03b through nine rounds.

How GS Verde Group Supports Medtech businesses

For MedTech businesses with ambition, navigating the path from spinout to scale and through to exit requires expert legal, financial, and commercial advice across the entire lifecycle.

At GS Verde Group, our multi-discipline corporate finance, legal, tax, accountancy, and communications work seamlessly together to provide end-to-end advisory services under one roof - enabling fast, effective results.

We help MedTech firms become high-growth businesses by:

• Securing investments
• Planning for exit and scalability
• Developing IP and protecting innovation
• Navigating commercial and regulatory complexity
• Structuring acquisitions, M&A and spinout

See our related Medtech sector deal here:3D marketing & sales platform's latest funding round raises substantial equity

To explore more about the top medtech companies in the UK, visit: Top Medtech Companies in the UK